Topics

Metabolic-Inflammatory-Fibrotic Interaction In Chronic Kidney Disease

Metabolic Diseases Chronic Inflammation Mitochondrial Dysfunction Oxidative Stress

Chronic kidney disease is sustained by a three-way interaction among metabolic reprogramming, nonresolving inflammation, and fibrosis. Repeated glomerular or tubular injury changes how renal epithelial, endothelial, stromal, and immune cells generate and use energy. Proximal tubular cells, normally dependent on fatty-acid oxidation, can lose oxidative capacity and accumulate lipids, while hypoxia and mitochondrial stress restrict ATP production. Lipid droplets can initially buffer excess fatty acids, but persistent cholesterol or fatty-acid imbalance becomes lipotoxic and promotes epithelial dysfunction. At the same time, activated leukocytes adopt metabolic programs that support cytokine production. These cell-type-specific shifts are not passive consequences of declining filtration; they influence whether tissue undergoes adaptive repair or advances toward scar formation[1][2][3].

Metabolic injury and inflammation reinforce one another. Damaged tubules release danger signals, chemokines, and cytokines that recruit monocytes and activate resident immune cells. Hypoxia develops through high tubular oxygen demand, capillary rarefaction, anemia, and impaired perfusion, stabilizing hypoxia-responsive pathways and increasing oxidative stress. Inflammatory mediators further disrupt mitochondrial and lipid metabolism, while metabolites can serve as signals that shape macrophage and lymphocyte phenotypes. This reciprocal circuit expands the population of activated fibroblasts and pericyte-derived myofibroblasts. TGF-beta signaling through SMAD3 integrates with angiotensin II, advanced glycation products, C-reactive protein, MAPK, and NF-kappaB pathways, thereby linking metabolic and inflammatory inputs to transcriptional programs for cell death, cytokine production, and extracellular-matrix deposition. Because fibrosis reflects several overlapping processes, interventions aimed at only one late endpoint may be insufficient; disrupting the metabolic-inflammatory-fibrotic feedback loop earlier is the more coherent therapeutic objective[1][3][4].

Fibrosis is the convergent structural outcome. After priming by persistent injury and inflammation, matrix-producing cells are activated and deposit collagens and other extracellular-matrix components. Tubular atrophy, microvascular loss, and tissue hypoxia then reduce functional reserve and maintain the fibrogenic environment. The scar itself alters tissue mechanics and cell-matrix signaling, making progression increasingly self-sustaining. Importantly, metabolic changes differ across podocytes, tubular segments, endothelial cells, fibroblasts, and immune subsets; a pathway that is protective in one cell type may be harmful in another. CKD cause and stage also matter. Consequently, bulk tissue measurements can obscure clinically relevant heterogeneity, and an isolated lipid, cytokine, or fibrosis marker cannot by itself define the dominant mechanism in an individual patient. This framework supports combination and precision strategies. Standard therapies that reduce hemodynamic and metabolic stress can indirectly lessen inflammatory and fibrotic signaling, while emerging approaches target lipid handling, mitochondrial function, hypoxia responses, immune-cell metabolism, TGF-beta-SMAD3 signaling, or matrix-producing cells[1][2][3][4][5].

Spatial and single-cell profiling may identify patients in whom lipid dysmetabolism, hypoxia, or a particular immune-stromal circuit is dominant. Success will require preserving beneficial repair and host defense while suppressing chronic pathogenic activation. Trials should establish target engagement in the relevant renal cell population and assess kidney function together with injury, inflammation, metabolic, and fibrosis biomarkers. Preclinical findings should also be checked against human biopsy, imaging, and longitudinal biomarker data, because animal models often emphasize one injury mechanism and may not reproduce the multimorbidity, medication exposure, or long timescale of human CKD. Human validation remains indispensable when selecting a metabolism-directed target[1][3][4].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-18739 Phorbol 12-myristate 13-acetate
Phorbol 12-myristate 13-acetate (PMA; TPA; Phorbol myristate acetate), a phorbol ester, is a dual SphK and protein kinase C (PKC) activator. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells (Validated by MedChemExpress).
PKC   SphK   NF-κB  
Prostate Cancer   Thyroid Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation  
863
HY-10256 Adezmapimod
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.
Organoid   p38 MAPK   Autophagy   Mitophagy   HSP  
Lung Cancer   Prostate Cancer   Gastric Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
642
HY-10071 Y-27632
Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade.
ROCK   Reactive Oxygen Species (ROS)   Akt   Ras   mTOR   Apoptosis   PAK   NADPH Oxidase   NF-κB   Autophagy  
Cancer   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis  
607
HY-13453 BAY 11-7082
BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells.
IKK   Deubiquitinase   Autophagy   Apoptosis   NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
510
HY-B0988 Deferoxamine mesylate
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
Autophagy   HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Apoptosis   Akt  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
454
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
317
HY-17026 Gemcitabine
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer.
Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis   Autophagy   Apoptosis   p38 MAPK  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
301
HY-10227 Bortezomib
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor   Ligands for Target Protein for PROTAC  
Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Obesity  
280
HY-13982 JSH-23
JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.
NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Obesity  
162
HY-10295 SB 202190
SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy.
Organoid   p38 MAPK   Autophagy   Apoptosis  
Lung Cancer   Prostate Cancer   Gastric Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
145
HY-10231 PX-478
PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis.
HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy  
Blood Disease   Type 1 Diabetes   Atherosclerosis  
117
HY-10261 Afatinib
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
EGFR   Autophagy   Apoptosis   c-Met/HGFR   Akt   p38 MAPK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Hepatitis C Virus Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
114
HY-13013 SIS3
SIS3 is a potent and selective inhibitor of Smad3 with an IC50 of 3 μM for Smad3 phosphorylation. SIS3 inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.
TGF-beta/Smad  
Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Lung Fibrosis  
113
HY-19696B Tauroursodeoxycholate dihydrate
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease.
Caspase   Apoptosis   Endogenous Metabolite   IRE1   NF-κB   JNK   Reactive Oxygen Species (ROS)   Akt  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis  
111
HY-40354 Tofacitinib
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.
JAK   STAT   NF-κB  
Depression   Pulmonary Disease   Systemic Lupus Erythematosus   Liver Injury   Rheumatoid Arthritis  
103
HY-100487 TAK-243
TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis.
E1/E2/E3 Enzyme   NF-κB   Apoptosis  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
97
HY-B0673 Pirfenidone
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
TGF-beta/Smad   CCR  
Colorectal Cancer   Prostate Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
97
HY-15893 DMOG
DMOG (Dimethyloxallyl Glycine) is a cell permeable and competitive inhibitor of HIF-PH, which results in HIF-1α stabilisation and accmulation in vitro and in vivo. DMOG is an α-ketoglutarate analogue and inhibits α-KG-dependent hydroxylases. DMOG acts as a pro-angiogenic agent and plays a protective role in experimental model of colitis and diarrhoea via HIF-1 related signal. DMOG induces cell autophagy.
HIF/HIF Prolyl-Hydroxylase   Autophagy  
Breast Cancer   Prostate Cancer   Ovarian Cancer  
88
HY-L018 TGF-beta/Smad Compound Library
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc. MCE designs a unique collection of 458 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Signaling Pathway Targeting Libraries

83
HY-L045 Oxygen Sensing Compound Library
Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival. HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O2 concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation. MCE offers a unique collection of 4,317 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Signaling Pathway Targeting Libraries

83
HY-L064 Glutamine Metabolism Compound Library
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,827 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Signaling Pathway Targeting Libraries

83
HY-L185 Anti-Fibrosis Compound Library
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Disease Focused Libraries

83
HY-L229 Nephrotoxicity Compound Library
Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure. MCE offers 160 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.
83
HY-L249 Lactylation Compound Library
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis. MCE has assembled a collection of 6,182 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Signaling Pathway Targeting Libraries

83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Signaling Pathway Targeting Libraries

83
HY-32735 Triptolide
Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor.
Environmental Pollutants   Apoptosis   NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity  
76
HY-17412 Minocycline hydrochloride
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
Bacterial   Antibiotic   HIF/HIF Prolyl-Hydroxylase   Apoptosis   MDM-2/p53   Potassium Channel   Calcium Channel  
Metabolic or Endocrine Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   SARS-CoV-2 Infection   Lung Fibrosis  
76
HY-18234A Leupeptin hemisulfate
Leupeptin hemisulfate is a broad-spectrum protease inhibitor. By inhibiting the activation of the PTEN/PI3K/Akt/NF-κB/ERK1/2/p38 signaling pathway, Leupeptin hemisulfate significantly reduces LPS-induced NO and ROS production, mitochondrial membrane potential hyperpolarization, phagocytic activity, pro-inflammatory cytokine release, and M1 polarization in mouse peritoneal macrophages, and reverses autophagic flux impairment. It also decreases Concanavalin A (HY-P2149)-induced proliferation index of mouse splenic lymphocytes and the Th1/IL-10 and Th2/IL-10 cytokine ratios, thereby modulating innate and adaptive immune responses. Leupeptin hemisulfate inhibits blood coagulation and tumorigenesis in mouse skin. Leupeptin hemisulfate can be used in research on chronic inflammatory diseases and skin tumorigenesis.

Source: Streptomyces roseus MB-26-AI

Ser/Thr Protease   Cathepsin   Autophagy   SARS-CoV   Atg8/LC3   NO Synthase   COX   p62   Arginase   PTEN   NF-κB   PI3K   Akt   p38 MAPK   ERK   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Respiratory Disease   Coronavirus Infection   Skin Disease  
69
HY-13426 Roxadustat
Roxadustat is an orally active hypoxia-inducible factor prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
HIF/HIF Prolyl-Hydroxylase   Ferroptosis  
Breast Cancer   Ovarian Cancer   SARS-CoV-2 Infection  
68
HY-101491 SR-18292
SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
PGC-1α   Autophagy  
Metabolic or Endocrine Disease  
67
HY-50876 Daporinad
Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression.
NAMPT   Autophagy   Apoptosis   mTOR   p38 MAPK   ERK  
Cancer  
67
HY-100347A SRI-011381 hydrochloride
SRI-011381 hydrochloride is an orally active TGF-β signaling agonist, exhibits neuroprotective effects, with blood-brain barrier permeability.
TGF-beta/Smad  
Neurological, Eye or Ear Disease   Liver Cancer  
61
HY-100347 SRI-011381
SRI-011381 is an orally active TGF-β signaling agonist, exhibits neuroprotective effects.
TGF-beta/Smad  
Neurological, Eye or Ear Disease   Liver Cancer  
61
HY-17538 ZLN005
ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).
PGC-1α   Autophagy  
Digestive System Disease   Digestive System Inflammation   Glucose Metabolism   Parkinson's Disease  
54
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
Dopamine Receptor   Autophagy   Mitophagy   COX   PGE synthase   Interleukin Related   p38 MAPK   Apoptosis   Caspase  
Breast Cancer   Parkinson's Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-15027 5-Aminosalicylic Acid
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
PPAR   PAK   NF-κB   Endogenous Metabolite  
Digestive System Disease   Colitis  
44
HY-N0055 Chlorogenic acid
Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb. It is an orally active antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension compound.
HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Bacterial   Influenza Virus   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Breast Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Cardiovascular Disease   Obesity  
38
HY-14654 Aspirin
Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
Environmental Pollutants   Apoptosis   Virus Protease   NF-κB   Mitophagy   p38 MAPK   Autophagy   COX   Caspase  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Non-Small Cell Lung Cancer   SARS-CoV-2 Infection   Obesity   Rheumatoid Arthritis  
38
HY-16268 Kartogenin
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research.
TGF-beta/Smad  
Inflammation or Immune System Disease   Liver Cancer  
33
HY-N0171A Beta-Sitosterol (purity>98%)
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
Bacterial   Apoptosis   Reactive Oxygen Species (ROS)   MDM-2/p53   Caspase   PARP   MMP   Bcl-2 Family   HIF/HIF Prolyl-Hydroxylase   TNF Receptor   Interleukin Related   NF-κB   mTOR   Lactate Dehydrogenase   CDK   Glutathione Peroxidase   SOD  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
25
HY-N1584 Halofuginone
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
DNA/RNA Synthesis   TGF-beta/Smad   Parasite   Sodium Channel   Calcium Channel  
Inflammation or Immune System Disease   Ovarian Cancer   Parasitic Infection   Pulmonary Hypertension  
22
HY-B0239 Chloramphenicol
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.

Source: Streptomyces venezuelae

Antibiotic   Bacterial   HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy   Apoptosis   Beclin1   JNK   Akt   MMP  
Infection   Respiratory Disease   Non-Small Cell Lung Cancer  
20
HY-N0439 Asiaticoside
Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
p38 MAPK   TGF-beta/Smad   Reactive Oxygen Species (ROS)   Apoptosis   Endogenous Metabolite  
Digestive System Disease   Lung Cancer   Neurodegenerative Disease   Pain   Digestive System Inflammation   Cardiovascular Disease  
19
HY-N0091 Hypoxanthine
Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite  
17
HY-125840 Belzutifan
Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC).
HIF/HIF Prolyl-Hydroxylase  
Breast Cancer   Pancreatic Cancer   Ovarian Cancer  
17
HY-N0378 D-Mannitol
D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells. D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed.
Environmental Pollutants   PGC-1α   Apoptosis   Adrenergic Receptor   Endogenous Metabolite   PKA  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity  
16
HY-N0390S1 L-Glutamine-13C5
L-Glutamine-13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
13
HY-116084 Trimethylamine N-oxide
Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.

Source: Host intestinal bacteria

Drug Metabolite   NOD-like Receptor (NLR)   Reactive Oxygen Species (ROS)   TGF-beta/Smad   Endogenous Metabolite  
Liver Cancer   Depression   Autoimmune Disease   Cardiovascular Disease  
12
HY-N0625A Alpinetin
Alpinetin is a flavonoid isolated from cardamom and possesses antitumor, antiinflammation, hepatoprotective, cardiovascular protective, lung protective, antibacterial, antiviral, neuroprotective properties. Alpinetin inhibits lipopolysaccharide (LPS)-induced inflammation, activates PPAR-γ, activates Nrf2, and inhibits TLR4 expression to protect LPS-induced renal injury.
PPAR   Keap1-Nrf2   Toll-like Receptor (TLR)  
Cancer   Digestive System Disease   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
9
HY-P80704 HIF1 alpha Antibody
HIF1 alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to HIF1 alpha.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

9
HY-B0130 Perindopril
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
Angiotensin-converting Enzyme (ACE)   NF-κB   STAT   Sirtuin  
Lung Cancer   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   Hypertension  
8
HY-113298 Citraconic acid
Citraconic acid (Methylmaleic acid) is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052).
NOD-like Receptor (NLR)   Keap1-Nrf2   Reactive Oxygen Species (ROS)  
Antioxidant Agent   Ischemia-Reperfusion Injury  
7
HY-B0504 Creatinine
Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
Endogenous Metabolite   GABA Receptor   iGluR  
Metabolic or Endocrine Disease   Prostate Cancer   Neurodegenerative Disease   SARS-CoV-2 Infection  
6
HY-B0504S Creatinine-d3
Creatinine-d3 is a deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
Isotope-Labeled Compounds   Endogenous Metabolite   iGluR   GABA Receptor  
Cancer   Metabolic or Endocrine Disease  
5
HY-P74888 HIF-1 alpha Protein, Human (His)
HIF-1 alpha is a key protein that responds to low oxygen levels. HIF-1 alpha Protein, Human (His) is the recombinant human-derived HIF-1 alpha protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

4
HY-108910 Chymotrypsin
Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin downregulates the TLR4/NF-κB signaling pathway, inhibiting the release of inflammatory factors, reducing cell infiltration and tissue damage. It also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54) and can be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions. It can be used in research on diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin can be used in studies of inflammation, edema, and expectoration.
Toll-like Receptor (TLR)   NF-κB   MMP  
Breast Cancer   Digestive System Inflammation   Gastric Disease   Metastatic Melanoma   Pharyngitis   Rheumatoid Arthritis  
3
HY-P99241 Ponsegromab
Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively. Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels. Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer.

Species: Human

TGF-beta/Smad   TGF-β Receptor  
Breast Cancer   Non-Small Cell Lung Cancer  
3
HY-P1420A TAT-cyclo-CLLFVY TFA
TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM.
HIF/HIF Prolyl-Hydroxylase  
2
HY-P1955 Etelcalcetide
Etelcalcetide (AMG 416; KAI-4169) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease.
CaSR  
Metabolic or Endocrine Disease  
2
HY-N3101 Pedalitin
Pedalitin is a tyrosinase and α-glucosidase inhibitor with IC50 values of 0.28 mM and 0.29 mM, respectively, and can be isolated and extracted from Rabdosia serra. Pedalitin is a xanthine oxidase (Xanthine Oxidase) (IC50 = 3.7 µM) and myeloperoxidase (MPO) (IC50 = 3.8 nM) inhibitor. Pedalitin ameliorates NAFLD by downregulating the EGFR/IRS1/AKT1/FOXO1 signaling pathway and related inflammatory and lipid metabolism factors. Pedalitin reduces the risk of urinary tract infection and stones by inhibiting the expression of the urease UreC gene in Proteus mirabilis. Pedalitin also exhibits antifungal activity, with a MIC of 3.9 mg/L against Cryptococcus neoformans. Pedalitin can be used for research on non-alcoholic fatty liver disease, chronic kidney disease, kidney stones, cryptococcosis, and abdominal pain.
Endogenous Metabolite   Tyrosinase   Glycosidase   Xanthine Oxidase   Glutathione Peroxidase   Fungal  
Digestive System Disease   Fungal Infection   Digestive System Inflammation   Chronic Kidney Disease   Kidney Stones  
2
HY-N2115 Araloside A
Araloside A (Chikusetsusaponin IV), triterpenoid saponins, is an orally active component of Aralia elata. Araloside A shows low-renin-inhibitory activity with an IC50 of 77.4 μM. Araloside A can inhibit cell proliferation and induce apoptosis. Araloside A suppresses inflammatory cytokines IL-1β and IL-6 production. Araloside A can be used for the researches of cancer, inflammation and cardiovascular disease, such as renal cell carcinoma and rheumatoid arthritis.
Renin   Apoptosis   Bcl-2 Family   Interleukin Related  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Hypertension   Rheumatoid Arthritis  
2
HY-P1420 TAT-cyclo-CLLFVY
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM.
HIF/HIF Prolyl-Hydroxylase  
2
HY-N0249 Saikosaponin C
Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection.
MMP  
Hepatitis C Virus Infection   Chronic Kidney Disease  
2
HY-N1990 Gypenoside XLIX
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
PPAR   Sirtuin   Keap1-Nrf2   Toll-like Receptor (TLR)   NF-κB   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   Apoptosis   Pyroptosis   Autophagy  
Neurological, Eye or Ear Disease   Atherosclerosis and Inflammation   Acute Lung Injury   Cardiomyopathy   Liver Injury  
2
HY-N0091S7 Hypoxanthine-15N4
Hypoxanthine-15N4 is the 15N labeled Hypoxanthine. Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite  
2
HY-107818 4-Hydroxychalcone
4-Hydroxychalcone is an orally active flavonoid precursor. 4-Hydroxychalcone inhibits VEGF- and bFGF-induced phosphorylation of ERK1/2 and Akt. 4-Hydroxychalcone suppresses resistant hypertension by alleviating hyperaldosteronism, inflammation and renal injury in cryptochrome gene knockout mice. 4-Hydroxychalcone possesses anti-angiogenic activity.
ERK   Akt  
Inflammation or Immune System Disease   Renal Disease   hCoV-OC43   Hypertension   Atrial Fibrillation  
2
HY-N0668 Rubusoside
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
GLUT   NF-κB   Amylases  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
2
HY-N0493 Pectolinarigenin
Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma.
COX   Lipoxygenase   NF-κB   p38 MAPK   ERK   HIF/HIF Prolyl-Hydroxylase   Keap1-Nrf2   PI3K   Apoptosis   Autophagy  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Neurodegenerative Disease   Rheumatoid Arthritis  
2
HY-P1955A Etelcalcetide hydrochloride
Etelcalcetide hydrochloride (AMG 416 hydrochloride; KAI-4169 hydrochloride) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease.
CaSR  
Metabolic or Endocrine Disease  
2
HY-B1472 Deoxycorticosterone acetate
Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria.
Mineralocorticoid Receptor  
Metabolic or Endocrine Disease   Hypertension  
2
HY-P99020 Fresolimumab
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease.

Species: Human

TGF-beta/Smad  
Inflammation or Immune System Disease   Melanoma   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Lung Fibrosis  
2
HY-W016562 Hippuric acid
Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research. .
Endogenous Metabolite   Keap1-Nrf2   MMP   Reactive Oxygen Species (ROS)   TGF-beta/Smad  
Colorectal Cancer   Cardiovascular Disease   Colitis   Hyperuricemia   Rheumatoid Arthritis  
2
HY-P2324A Gramicidin A TFA
Gramicidin A (TFA) is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A (TFA) is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A (TFA) induces degradation of hypoxia inducible factor 1 α (HIF-1α).
Antibiotic   Bacterial  
Infection  
1
HY-17609A Difelikefalin hydrochloride
Difelikefalin hydrochloride (CR-845 hydrochloride; FE-202845 hydrochloride) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin hydrochloride reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin hydrochloride suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin hydrochloride can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis.
Opioid Receptor   Interleukin Related  
Renal Disease   Atopic Dermatitis  
1
HY-111372S1 Finerenone-d5
Finerenone-d5 (BAY 94-8862-d5) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
Isotope-Labeled Compounds   Mineralocorticoid Receptor  
Blood or Cardio-cerebrovascular Disease  
1
HY-P10869 dCNP
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses.
Natriuretic Peptide Receptor (NPR)  
Cancer   Inflammation or Immune System Disease  
1
HY-N9447 Norbergenin
Norbergenin is a polyphenolic isocoumarin derivative. Norbergenin acts as a non-competitive inhibitor of bovine adrenal tyrosine hydroxylase (TH) with a Ki value of 69.6 μM. Norbergenin inhibits lipopolysaccharide-induced inflammatory responses in macrophages by suppressing the activation of NF-κB, MAPK and STAT3, as well as blocking metabolic reprogramming. Norbergenin inhibits aluminum chloride-induced oxidative stress and apoptosis and restores neurocognitive parameters. Norbergenin scavenges ROS through multiple mechanisms and protects cell membranes from lipid peroxidation damage. Norbergenin can be used in research related to Alzheimer's disease, peptic ulcer and arthritis.
Free Radical Scavengers   Tyrosine Hydroxylase   Reactive Oxygen Species (ROS)   Apoptosis   NF-κB   p38 MAPK   STAT  
Inflammation or Immune System Disease   Peptic Ulcer Disease   Arthritis   Alzheimer's Disease  
1
HY-N0091S Hypoxanthine-13C5,15N4
Hypoxanthine-13C5,15N4 is a 15N-labeled and 13C-labled Hypoxanthine (HY-N0091). Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite   Isotope-Labeled Compounds  
1
HY-N2035 Moslosooflavone
Moslosooflavone is a flavonoid isolated from Andrographis paniculata. Moslosooflavone has an anti-hypoxia and anti-inflammatory activities.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease  
1
HY-N0091S6 Hypoxanthine-d2
Hypoxanthine-d2 is the deuterium labeled Hypoxanthine. Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite  
1
HY-N3307 (+)-Medioresinol
(+)-Medioresinol is a furofuran-type lignan with antifungal and antibacterial properties. (+)-Medioresinol synergizes with antibiotics to exert antimicrobial and antibiofilm effects. (+)-Medioresinol induces intracellular ROS accumulation and mitochondrial-mediated apoptosis in Candida albicans. (+)-Medioresinol inhibits LPS (HY-D1056)-stimulated IL-12p40 production. (+)-Medioresinol is a PGC-1α activator that protects against endothelial cell pyroptosis in ischemic stroke via the PPARα-GOT1 axis. (+)-Medioresinol can be used in research on fungal and bacterial infection, inflammation, and ischemic stroke.
Bacterial   Fungal   Reactive Oxygen Species (ROS)   Apoptosis   MMP   Interleukin Related   PI3K   Akt   mTOR   PPAR   PGC-1α   Pyroptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-P99121 Anti-Mouse/Human CD11b Antibody (M1/70)
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer.

Species: Mouse

Integrin  
Cancer   Inflammation or Immune System Disease  
1
HY-N2263 Skimmin
Skimmin (Umbelliferone glucoside) is a major pharmacologically active and orally active molecule present in Hydrangea paniculata, a medical herb used in traditional Chinese medicine as an anti-inflammatory agent. Skimmin has renal protective activity. Skimmin can improve creatinine clearance, and reduce plasma creatinine, and kidney injuries. Skimmin has good anti-amoebic activity against the HM1:IMMS strain of Entamoeba histolytica. Skimmin has anti-cancer and neuroprotective activities. Skimmin reduces cardiac fibrosis as well as decreasing TNF-α, IL-6, IL1β, and TGFβ1 in cardiac tissues. Skimmin can be studied in research for diabetes and diabetes-related diseases.
Interleukin Related   TGF-β Receptor   TNF Receptor   Parasite  
Prostate Cancer   Pancreatic Cancer   Parasitic Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   Glucose Metabolism  
1
HY-N2013 Aristolactam I
Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
Drug Metabolite   Aquaporin   Cadherin   TGF-beta/Smad  
Metabolic or Endocrine Disease   Breast Cancer   Liver Cancer  
1
HY-P10899 ETTAC-2
ETTAC-2 is a LRG1 PROTAC degrader, degrading LRG1 via the ubiquitin-proteasome pathway with a DC50 value of 8.38 μM. ETTAC-2 penetrates damaged renal cells to reduce the extracellular secretion of LRG1. ETTAC-2 effectively inhibits the TGF-β-Smad3 signaling pathway and diminishes the secretion of fibrosis-associated extracellular matrix proteins. ETTAC-2 degrades LRG1 within fibrotic kidneys and the efficacy in inhibiting the TGF-β-Smad3 pathway both in vitro and vivo. ETTAC-2 can be used for renal fibrosis research.
PROTACs   TGF-beta/Smad  
Urogenital Disease  
1
HY-P2324 Gramicidin A
Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α).
Bacterial   HIF/HIF Prolyl-Hydroxylase   Antibiotic  
Cancer   Infection  
1
HY-N2995 Poricoic acid A
Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin.
NF-κB   Keap1-Nrf2   AMPK   TGF-beta/Smad   Reactive Oxygen Species (ROS)  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   Parkinson's Disease   Obesity   Lung Fibrosis  
1
HY-17609 Difelikefalin
Difelikefalin (CR-845; FE-202845) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis.
Opioid Receptor   Interleukin Related  
Renal Disease   Atopic Dermatitis  
1
HY-P99590A Sotatercept (mIgG2a)
Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic).
TGF-β Receptor   TGF-beta/Smad  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
1
HY-B0504S5 Creatinine-15N
Creatinine-15N (NSC13123-15N) is the 15N-labeled Creatinine (HY-B0504). Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
Isotope-Labeled Compounds   Endogenous Metabolite   iGluR   GABA Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-P1888A HIF-1 alpha (556-574) TFA
HIF-1 alpha (556-574) TFA is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis.
HIF/HIF Prolyl-Hydroxylase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11354 THR-123
THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis.
TGF-β Receptor   Apoptosis   Interleukin Related   Integrin   Cadherin  
Inflammation or Immune System Disease  
/
HY-117985BS Evogliptin-d9 tartrate
Evogliptin-d9 tartrate (DA-1229-d9 tartrate) is the deuterium labeled Evogliptin tartrate (HY-117985B). Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
Isotope-Labeled Compounds   Dipeptidyl Peptidase   Autophagy  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P6441 KP-6
KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD).
β-catenin   Wnt  
Inflammation or Immune System Disease  
/
HY-N20057 Rhizoma menispermi extract
Rhizoma menispermi extract is an extract of Menispermum dauricum DC, which has anti-cancer and anti-hypoxia activities.
Others  
Cancer  
/
HY-N10330 7-Hydroxyneolamellarin A
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer.

Source: Dendrilla nigra

HIF/HIF Prolyl-Hydroxylase   VEGFR  
/
HY-P10852 TAT-MKK3b
TAT-MKK3b is a p38 peptide inhibitor. TAT-MKK3b can inhibit p38 phosphorylation. TAT-MKK3b has renal targeting, ROS-scavenging, and ferroptosis-mitigating capabilities. TAT-MKK3b improves acute kidney injury and its progression to chronic kidney disease.
p38 MAPK   Ferroptosis   Reactive Oxygen Species (ROS)  
Metabolic or Endocrine Disease  
/
HY-D3234 Cy-AP
Cy-AP is a hypoxia-sensitive near-infrared Fluorescent probe (emission wavelength: 725 nm). Cy-AP exhibits no fluorescence under normoxic microenvironments, while under hypoxic microenvironments, its azo group is reduced, releasing strong near-infrared fluorescence with an emission at 725 nm. Cy-AP enables visualization of intracellular hypoxic status through multiple imaging modalities.
Fluorescent Dye  
/
HY-W616806 Sodium 6-oxo-3,6-dihydropurin-7-ide
Sodium 6-oxo-3,6-dihydropurin-7-ide, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Biochemical Assay Reagents  
/
HY-P3445 Anrikefon
Anrikefon is a peripherally restricted kappa opioid receptor (KOR) agonist, with an IC50 of 0.54 nM, an EC50 of 2.41 pM, and a Ka of 0.068 nM against human KOR, and it exhibits high selectivity over μ and δ opioid receptors. Anrikefon exerts analgesic effects by inhibiting behaviors associated with inflammatory, postoperative and neuropathic pain, and also exerts antipruritic effects by reducing itch-related behaviors. Anrikefon can be used in research on pain, pruritus, and pruritus associated with chronic kidney disease.
Opioid Receptor  
Neurological, Eye or Ear Disease  
/
HY-P11297 AC-SDKP-NH2
AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research.
Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10414 Klotho-derived peptide 1
Klotho-derived peptide 1 (KP1 (human)) is a polypeptide with multiple activities including senescence inhibition and renal protection. Klotho-derived peptide 1 binds to TβR2 and ATAD3A, with a Kd value of 1.41 μM for binding to human TβR2 and a Kd value of 0.319 μM for binding to ATAD3A. By binding to TβR2, Klotho-derived peptide 1 blocks the TGF-β/Smad3 and downstream TGF-β signaling pathways, inhibits the expression of miR-223-3p, induces the expression of lncRNA-TUG1, restores endogenous Klotho at the post-transcriptional level, inhibits cellular senescence markers, fibroblast activation and renal tubular epithelial cell apoptosis, blocks cytochrome c release and caspase activation, maintains the integrity of mitochondrial ultrastructure, and restores mitochondrial protein levels. Klotho-derived peptide 1 enters renal tubular epithelial cells via endocytosis, protects against nephrotoxic and hypoxic injuries, and recapitulates the renal protective and anti-fibrotic effects of full-length Klotho. Klotho-derived peptide 1 can be used in research related to kidney diseases such as chronic kidney disease and SARS-CoV-2-associated acute kidney injury.
TGF-β Receptor  
Renal Disease   SARS-CoV-2 Infection  
/
HY-N12041 Axl-IN-16
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression.

Source: Hericium erinaceus,Monascus

TAM Receptor   HIF/HIF Prolyl-Hydroxylase  
Cancer  
/
HY-105129AS Pimonidazole-d10
Pimonidazole-d10 is the deuterium labeled Pimonidazole. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
Isotope-Labeled Compounds  
/
HY-P10223 Cyclo(CRVIIF)
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 65 and 123 μM, respectively.
HIF/HIF Prolyl-Hydroxylase  
Cancer  
/
HY-13690S2 Mitotane-d8
Mitotane-d8 is the deuterium labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions.
Apoptosis  
Cancer  
/
HY-127022 Anisodine
Anisodine (Daturamine) is a neuroprotective compound that reduces exacerbated M1, M2, M4, and M5 receptor expression in brain tissues under hypoxia/reoxygenation conditions. Anisodine inhibits calcium ion influx and reactive oxygen species (ROS)levels. Anisodine leads to decreased aspartate levels during hypoxia.
mAChR   Calcium Channel   Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease  
/
HY-W011254 Ac-VAD-CHO
Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor. Ac-VAD-CHO inhibits dissipation of MMP and cytochrome c release in hypoxia-exposed cells.
Caspase  
Cancer  
/
HY-N20240 Tremella extract
Tremella extract (Tremella fuciformis extract) is an extract of Tremella (a type of tremella fungus) that has anti-fatigue and anti-hypoxia effects.
Others  
Neurological, Eye or Ear Disease  
/
HY-13690S3 Mitotane-13C12
Mitotane-13C12 (2,4′-DDD-13C12) is 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions.
Isotope-Labeled Compounds   Apoptosis  
Cancer  
/
HY-17609S Difelikefalin-d5
Difelikefalin-d5 (CR-845-d5; FE-202845-d5) is the deuterated-labeled Difelikefalin (HY-17609). Difelikefalin (CR-845; FE-202845) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis.
Isotope-Labeled Compounds   Opioid Receptor   Interleukin Related  
Renal Disease   Atopic Dermatitis  
/
HY-14744S Levamlodipine-d4
Levamlodipine-d4 is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis.
Isotope-Labeled Compounds   Calcium Channel   MMP  
/
HY-B0130AS Perindopril-d3 erbumine
Perindopril-d3 (erbumine) is deuterated labeled Perindopril (erbumine) (HY-B0130A). Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
NF-κB   Angiotensin-converting Enzyme (ACE)   Sirtuin   STAT   Isotope-Labeled Compounds  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N0091S4 Hypoxanthine-13C2,15N-1
Hypoxanthine-13C2,15N-1 is a 15N-labeled and 13C-labled Hypoxanthine (HY-N0091). Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-101277S1 Vadadustat-13C6
Vadadustat-13C6 (PG-1016548-13C6) is 13C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo.
Isotope-Labeled Compounds   HIF/HIF Prolyl-Hydroxylase  
Blood or Cardio-cerebrovascular Disease  
/
HY-N0668R Rubusoside (Standard)
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
GLUT   Reference Standards   NF-κB   Amylases  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N2035R Moslosooflavone (Standard)
Moslosooflavone (Standard) is the analytical standard of Moslosooflavone. This product is intended for research and analytical applications. Moslosooflavone is a flavonoid isolated from Andrographis paniculata. Moslosooflavone has an anti-hypoxia and anti-inflammatory activities.
Reference Standards   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease  
/
HY-N0272R Eleutheroside E (Standard)
Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis.
Reference Standards   Others  
Inflammation or Immune System Disease  
/
HY-N0091S1 Hypoxanthine-13C,15N2
Hypoxanthine-13C,15N2 is a 15N-labeled and 13C-labled Hypoxanthine (HY-N0091). Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Bacterial  
Infection  
/
HY-W015466R Acetylvaline (Standard)
Acetylvaline (Standard) is the analytical standard of Acetylvaline (HY-W015466). This product is intended for research and analytical applications. Acetylvaline is a class of amino acid derivative metabolites. The expression abundance of Acetylvaline is upregulated under heat stress conditions; it participates in the regulation of amino acid biosynthesis, cysteine and methionine metabolic pathways, and mediates the physiological processes of antioxidant defense and energy metabolism reprogramming in Magallana sikamea. Acetylvaline can be released from acetylvalyl-RNA of Turnip Yellow Mosaic Virus (TYMV) by N‑acylaminoacyl‑tRNA hydrolase. Acetylvaline can be used in metabolism-related research.
Reference Standards   Endogenous Metabolite   Amino Acid Derivatives  
Metabolic or Endocrine Disease  
/
HY-N16435 Plumericin
Plumericin is an anti-inflammatory, antioxidant, and antibacterial agent. Plumericin reduces Apoptosis, promotes Nrf-2 and inhibits NF-κB and AhR activation, blocks STAT3 signaling. Plumericin inhibits Mycobacterium tuberculosis growth. Plumericin can be used for the research of chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis.
Bacterial   Apoptosis   Keap1-Nrf2   NF-κB   Aryl Hydrocarbon Receptor   STAT  
Digestive System Disease   Cardiovascular Disease   Renal Disease   Mycobacterium Tuberculosis Infection   Colitis  
/
HY-N2013R Aristolactam I (Standard)
Aristolactam I (Standard) is the analytical standard of Aristolactam I. This product is intended for research and analytical applications. Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
Reference Standards   Caspase   Apoptosis  
Inflammation or Immune System Disease  
/
HY-117985S Evogliptin-d9
Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
Isotope-Labeled Compounds   Dipeptidyl Peptidase   Autophagy  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-B0627S1 Metformin-13C2 hydrochloride
Metformin-13C2 (1,1-Dimethylbiguanide-13C2) hydrochloride is the 13C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
Isotope-Labeled Compounds   Mitophagy   Autophagy   mTOR   AMPK   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-17609S1 Difelikefalin-d5 hydrochloride
Difelikefalin-d5 hydrochloride (CR-845-d5 hydrochloride; FE-202845-d5 hydrochloride) is the deuterated-labeled Difelikefalin (HY-17609). Difelikefalin (CR-845; FE-202845) is an orally active peripherally acting kappa opioid receptor agonist. Difelikefalin reduces acute kidney injury, decreases oliguria, maintains urine flow, inhibits cytokine expression, and improves survival in endotoxemia after ischemia/reperfusion. Difelikefalin suppresses pruritus signals and exhibits neuromodulatory antipruritic activity. Difelikefalin can be used in research related to acute kidney injury, chronic kidney disease-associated pruritus, and atopic dermatitis.
Isotope-Labeled Compounds   Opioid Receptor   Interleukin Related  
Renal Disease   Atopic Dermatitis  
/
HY-B0627S Metformin-d6
Metformin-d6 (1,1-Dimethylbiguanide-d6) is a deuterated labeled Metformin (HY-B0627). Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
Isotope-Labeled Compounds   Mitophagy   Autophagy   mTOR   AMPK   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P990965 Efparepoetin alfa
Efparepoetin alfa is an EPO receptor agonist. Efparepoetin alfa can be used in the research of anemia caused by chronic kidney disease.

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-13426S Roxadustat-d5
Roxadustat-d5 is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
HIF/HIF Prolyl-Hydroxylase   Ferroptosis  
Cancer  
/
HY-N6905 Acetylarenobufagin
Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-I) modulator.

Source: toad

HIF/HIF Prolyl-Hydroxylase  
Cancer  
/
HY-N10359 Isoandrographolide
Isoandrographolide is an orally active NLRP3 inflammasome inhibitor and AKT/GSK-3β/β-catenin pathway inhibitor. Isoandrographolide inhibits the expression of NLRP3, ASC, and caspase-1, and reduces the levels of phosphorylated AKT, phosphorylated GSK-3β, and β-catenin. Isoandrographolide alleviates inflammatory responses, reduces collagen deposition, suppresses epithelial-mesenchymal transition (EMT), induces differentiation of leukemia cells, inhibits the growth of leukemia cells, protects lung and kidney tissues, regulates cytokine levels, and also exhibits hepatoprotective effects. Isoandrographolide can be used in studies related to silicosis, murine myeloid leukemia, renal tubulointerstitial fibrosis, and non-alcoholic fatty liver disease.
NOD-like Receptor (NLR)   Caspase   Akt   GSK-3   β-catenin  
Inflammation or Immune System Disease   Pulmonary Disease   Acute Myeloid Leukemia   Fatty Liver Disease  
/
HY-P991881 KY1070
KY1070 is a fully human anti-BMP6 antibody with a Kd of 0.00014 μM against the human BMP6. It exhibits high specificity for BMP6, showing no cross-reactivity with other members of the BMP family, and effectively inhibits BMP6-induced BMP receptor heterodimerization and hepcidin expression. KY1070 modulates Ferroportin expression on erythroid progenitor cells and accelerates erythropoiesis. In rodent anemia models, KY1070 reduces the required dose of erythropoietin (EPO) when used in combination with EPO and enhances the responsiveness of mice with chronic kidney disease (CKD)-associated anemia to EPO treatment. KY1070 is applicable for research on anemia of chronic disease .

Species: Human

TGF-β Receptor   Hepcidin   Ferroportin  
Blood Disease  
/
HY-111372S Finerenone-d3
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
Mineralocorticoid Receptor  
/
HY-P11178 Corisin
Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF).
Apoptosis   SARS-CoV  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-13690S1 Mitotane-13C6
Mitotane-13C6 is the 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions.
Apoptosis  
Cancer  
/
HY-N0091S3 Hypoxanthine-13C2,15N
Hypoxanthine-13C2,15N is a 15N-labeled and 13C-labled Hypoxanthine (HY-N0091). Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-P10426 cyclo(CLLFVY)
cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers.
HIF/HIF Prolyl-Hydroxylase   VEGFR  
Cancer  
/
HY-P1888 HIF-1 alpha (556-574)
HIF-1 alpha (556-574) is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis.
HIF/HIF Prolyl-Hydroxylase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11354A THR-123 TFA
THR-123 TFA is an orally active ALK3 peptide agonist. THR-123 TFA has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 TFA suppresses inflammation, Apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 TFA can be used for the study of kidney fibrosis.
TGF-β Receptor   Apoptosis   Interleukin Related   Integrin   Cadherin  
Chronic Kidney Disease  
/
HY-P5314 OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research.
EGFR   STAT  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Hepatitis C Virus Infection   Obesity  
/
HY-P3455 Ac-SVVVRT-NH2
Ac-SVVVRT-NH2 is a PGC-1α modulator that modulates the activity of the human PGC-1α promoter (114%). Ac-SVVVRT-NH2 increases PGC-1α mRNA (125%) and accumulation of intracellular lipids (128%) in subcutaneous human adipocytes. Ac-SVVVRT-NH2 can be used in the research of diseases which is modulated by PGC-1α.
PGC-1α  
Cancer   Metabolic or Endocrine Disease  
/
HY-N2160 6'''-Feruloylspinosin
6'''-Feruloylspinosin is an orally active RORα activator that crosses the blood-brain barrier, with a Kd of 0.308 μM, and is found in natural sources. 6'''-Feruloylspinosin modulates AMPK and mTOR phosphorylation. 6'''-Feruloylspinosin promotes autophagy through the AMPK/mTOR signaling pathway, inhibits GSK3β phosphorylation at Tyr216, and activates the PGC-1α/Nrf2/HO-1 pathway. 6'''-Feruloylspinosin regulates neurotransmitter levels, enhances mRNA expression of GABAA α1, α5, and GABAB R1 receptor subunits, increases brain 5-HT and GABA, restores melatonin levels, and ameliorates anxiety-like behaviors. 6'''-Feruloylspinosin regulates oxidative stress homeostasis, inhibits mitochondrial dysfunction, decreases MDA while increasing GSH. 6'''-Feruloylspinosin can be used for research on Alzheimer's disease, acute myocardial infarction, heart failure with insomnia, and insomnia.
ROR   AMPK   mTOR   Autophagy   GSK-3   PGC-1α   Keap1-Nrf2   GABA Receptor   5-HT Receptor  
Sleep-Wake Disorder   Alzheimer's Disease   Myocardial Infarction   Heart Failure  
/
HY-P990061 Polzastobart
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

Transmembrane Glycoprotein   LILRB  
Cancer   Inflammation or Immune System Disease  
/
HY-113239 Hydroxycotinine
Hydroxycotinine is a nicotine metabolite commonly found in the urine of smokers. Hydroxycotinine is the primary biomarker of tobacco/nicotine vapor exposure, formed from the conversion of nicotine via cotinine. Hydroxycotinine serum levels in rodents are influenced by sex and co-exposure to nicotine vapor and ethanol. Hydroxycotinine elevation is associated with decreased eGFR and increased risk of chronic kidney disease. Hydroxycotinine can be used in research related to chronic kidney disease.
Drug Metabolite  
Metabolic or Endocrine Disease   Chronic Kidney Disease  
/
HY-N0091S2 Hypoxanthine-13C5
Hypoxanthine-13C5 is a 13C-labeled Hypoxanthine (HY-N0091). Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-B0504S1 Creatinine-13C
Creatinine-13C is the 13C-labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
Isotope-Labeled Compounds   Endogenous Metabolite   iGluR   GABA Receptor  
Metabolic or Endocrine Disease  
/
HY-B0678 Metaxalone
Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia.
NF-κB   PGC-1α  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Parkinson's Disease   Obesity  
/
HY-N9941 2,8-Dihydroxyadenine
2,8-Dihydroxyadenine is an endogenous metabolite that forms crystals in urine, leading to kidney stone formation and crystal deposition in the kidney. 2,8-Dihydroxyadenine induces crystal-induced tubular injury, inflammation, and fibrosis through crystal deposition in renal tubules, where crystals are excreted in urine, internalized by tubular epithelial cells, and transported to the interstitium. 2,8-Dihydroxyadenine upregulates CD44 expression near crystals, TNF-α signaling through NF-κB, and mTORC1 signaling, while inducing actin stress fiber formation and cytoskeletal remodeling. 2,8-Dihydroxyadenine downregulates epithelial-mesenchymal transition pathways and oxidative phosphorylation, and induces changes affecting inflammation, metabolism, and cell cycle regulation. 2,8-Dihydroxyadenine can be used in research on kidney disease, adenine phosphoribosyltransferase deficiency, and kidney stone disease.
Endogenous Metabolite   NF-κB   TNF Receptor   mTOR   Oxidative Phosphorylation  
Chronic Kidney Disease   Kidney Stones  
/
HY-114557 NSC 90469
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity.
JNK   NF-κB   Sirtuin   PGC-1α   COX   TGF-β Receptor   Collagen  
Digestive System Disease   Autoimmune Disease   Digestive System Inflammation   Obesity   Hypothyroidism  
/
HY-156430 MMP-7-IN-3
MMP-7-IN-3 is a potent and selective inhibitor of MMP-7. MMP-7-IN-3 suppresses kidney fibrosis progression in a mouse model with unilateral ureteral obstruction.
MMP  
Pancreatic Cancer   Pain   Lung Fibrosis  
/
HY-N0204 Pulchinenoside A
Pulchinenoside A (Anemoside A3) is an orally active triterpenoid glycoside found in the root of Pulsatilla chinensis. Pulchinenoside A has amti-inflammation, antitumor, antidepressant, immunoregulatory and neuroprotective efrects. Pulchinenoside A activates NF-κB/MAPK signaling pathway. Pulchinenoside A can induce relaxing effect in rat renal arteries. Pulchinenoside A can be used for the researches of experimental autoimmune encephalomyelitis, breast cancer, depression and renovascular hypertension.
NF-κB   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-W015466 Acetylvaline
Acetylvaline is a class of amino acid derivative metabolites. The expression abundance of Acetylvaline is upregulated under heat stress conditions; it participates in the regulation of amino acid biosynthesis, cysteine and methionine metabolic pathways, and mediates the physiological processes of antioxidant defense and energy metabolism reprogramming in Magallana sikamea. Acetylvaline can be released from acetylvalyl-RNA of Turnip Yellow Mosaic Virus (TYMV) by N‑acylaminoacyl‑tRNA hydrolase. Acetylvaline can be used in metabolism-related research.
Endogenous Metabolite   Amino Acid Derivatives  
Metabolic or Endocrine Disease  
/
HY-N0091R Hypoxanthine (Standard)
Hypoxanthine (Standard) is the analytical standard of Hypoxanthine. This product is intended for research and analytical applications. Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Reference Standards   Endogenous Metabolite  
/
HY-N2909 Aurantiamide
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models.
NF-κB   RIP kinase   Mixed Lineage Kinase  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Alzheimer's Disease   Parkinson's Disease   Obesity  
/
HY-N3686 D-Arabitol
D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
AMPK   PGC-1α  
Obesity  
/
HY-47030 Ferric citrate hydrate
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research.
Environmental Pollutants   Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-B0504R Creatinine (Standard)
Creatinine (Standard) is the analytical standard of Creatinine. This product is intended for research and analytical applications. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
Reference Standards   Endogenous Metabolite   iGluR   GABA Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-110228 Metformin-d6 hydrochloride
Metformin-d6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
Isotope-Labeled Compounds   AMPK   Autophagy   Mitophagy   Apoptosis   mTOR  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-N0091S5 Hypoxanthine-d4
Hypoxanthine-d4 is the deuterium labeled Hypoxanthine. Hypoxanthine, a purine derivative, is a potential free radical generator and could be used as an indicator of hypoxia.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-P99505 Ziltivekimab
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease.

Species: Human

Interleukin Related   LDLR  
Renal Disease   Atherosclerosis and Inflammation  
/
HY-N0378R D-Mannitol (Standard)
D-Mannitol (Standard) is the analytical standard of D-Mannitol (HY-N0378). This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells. D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed.
Reference Standards   PGC-1α   Apoptosis   PKA   Endogenous Metabolite   Adrenergic Receptor  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-B0504S2 Creatinine-d5
Creatinine-d5 is the deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
Isotope-Labeled Compounds   Endogenous Metabolite   iGluR   GABA Receptor  
Metabolic or Endocrine Disease  
/
HY-113493 4-Pyridoxic acid
4-Pyridoxic acid is an endogenous substrate of renal organic anion transporters (OAT1/3) and a catabolite of vitamin B6. 4-Pyridoxic acid is excreted through OAT1/3-mediated tubular active secretion, which can reflect OAT1/3 activity. Elevated plasma concentrations of 4-Pyridoxic acid are associated with decreased OAT1/3 activity in chronic kidney disease (CKD) and can be used as a biomarker to reflect the severity of knee osteoarthritis (KOA) and lumbar spondylosis (LS).
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-108775A Sodium thiosulfate (99%, water≤1.0%)
Sodium thiosulfate (Sodium hyposulfite) is an antioxidant. Sodium thiosulfate inhibits the expression of p-GSK-3β and β-catenin proteins, reduces IL-1β, COX-2, and Iba-1, and inhibits NFκB activation. Sodium thiosulfate promotes angiogenesis, inhibits inflammation, and improves acute lung injury. Sodium thiosulfate also exhibits anti-cancer activity against melanoma. Sodium thiosulfate also exerts renal protective effects. Sodium thiosulfate can be used in the research of osteoarthritis, brain inflammation, cancer (such as breast cancer, melanoma), and kidney disease.
COX   β-catenin   NF-κB   Interleukin Related   GSK-3  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease   Breast Cancer   Melanoma   Antioxidant Agent   Osteoarthritis  
/
HY-P703327 EGLN1 Protein, Human (246a.a, His)
EGLN1 Protein, Human (246a.a, His) is the recombinant human-derived EGLN1, expressed by E. coli , with His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P70943 HYOU1 Protein, Human (HEK293, His)
The HYOU1 protein plays a crucial role in coordinating cytoprotective mechanisms in response to hypoxia, indicating its importance in cellular stress responses. It involves a potential molecular chaperone function and is actively involved in the protein folding process. HYOU1 Protein, Human (HEK293, His) is the recombinant human-derived HYOU1 protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Human; Source: HEK293

/
HY-P706012 EGLN1 Protein, Human (His)

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P706141 SESN2 Protein, Human (His)

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P84619 HIF1 alpha Antibody (YA4316)
HIF1 alpha Antibody (YA4316) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HIF1 alpha.

Host: Mouse; Reactivity: Human, Mouse, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P87793 HIF-1α Antibody (YA7478)
HIF-1α Antibody (YA7478) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to HIF-1α.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85711 HIF1 alpha Antibody (YA5403)
HIF1 alpha Antibody (YA5403) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P80705 HIF1 beta Antibody (YA385)
HIF1 beta Antibody (YA385) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF1 beta.

Host: Rabbit; Reactivity: Human, Mouse, Rat, Hamster

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81153 HIF-2 alpha Antibody (YA3517)
HIF-2 alpha Antibody (YA3517) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF-2 alpha.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80705A HIF1 beta Antibody (YA385)(PBS only)
HIF1 beta Antibody (YA385) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF1 beta.

Host: Rabbit; Reactivity: Human, Mouse, Rat, Hamster

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84619A HIF1 alpha Antibody (YA4316)(PBS only)
HIF1 alpha Antibody (YA4316) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HIF1 alpha.

Host: Mouse; Reactivity: Human, Mouse, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P85201 HIF1 alpha Antibody (YA4893)
HIF1 alpha Antibody (YA4893) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P85750 HIF1 beta Antibody (YA5442)
HIF1 beta Antibody (YA5442) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HIF1 beta.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/

Keywords

chronic kidney disease | metabolic reprogramming | renal inflammation | kidney fibrosis | hypoxia | lipotoxicity